{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:34:21Z","timestamp":1787751261390,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12902-018-0325-4","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T23:52:45Z","timestamp":1545868365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A case of malignant insulinoma responsive to somatostatin analogs treatment"],"prefix":"10.1186","volume":"18","author":[{"given":"Mariasmeralda","family":"Caliri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Verdiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Landoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Burato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Maria","family":"Rotella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Peri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,27]]},"reference":[{"key":"325_CR1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.bpg.2005.06.002","volume":"19","author":"K Oberg","year":"2005","unstructured":"Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753\u201381.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"325_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/cncr.21179","volume":"104","author":"B Hirshberg","year":"2005","unstructured":"Hirshberg B, Cochran C, Skarulis MC, Libutti SK, Alexander HR, Wood BJ, et al. Malignant insulinoma: spectrum of unusual clinical features. Cancer. 2005;104:264\u201372.","journal-title":"Cancer"},{"key":"325_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.bpg.2005.05.008","volume":"19","author":"CS Grant","year":"2005","unstructured":"Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19:783\u201398.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"325_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000095926","volume":"115","author":"YM Jonkers","year":"2006","unstructured":"Jonkers YM, Claessen SM, Veltman JA, Geurts van Kessel A, Din-jens WN, Skogseid B, et al. Molecular parameters associated with insulinoma progression: chromosomal instability versus p53 and CK19 status. Cytogenet Genome Res. 2006;115:289\u201397.","journal-title":"Cytogenet Genome Res"},{"key":"325_CR5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1677\/ERC-08-0017","volume":"15","author":"UF Pape","year":"2008","unstructured":"Pape UF, Berndt U, M\u00fcller-Nordhorn J, B\u00f6hmig M, Roll S, Koch M, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008;15:1083\u201397.","journal-title":"Endocr Relat Cancer"},{"key":"325_CR6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/cncr.23549","volume":"113","author":"UF Pape","year":"2008","unstructured":"Pape UF, Jann H, M\u00fcller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113:256\u201365.","journal-title":"Cancer"},{"key":"325_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ando.2013.07.001","volume":"74","author":"B E","year":"2013","unstructured":"E B, Caron P, Lombard-Bohas C, Tabarin A, Mitry E, Reznick Y, et al. Malignant insulinoma: recommendations for characterisation and treatment. Ann Endocrinol. 2013;74:523\u201333.","journal-title":"Ann Endocrinol"},{"key":"325_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/00000478-200608000-00018","volume":"30","author":"A Perren","year":"2006","unstructured":"Perren A, Wiesli P, Schmid S, Montani M, Schmitt A, Schmid C, et al. Pancreatic endocrine tumors are a rare manifestation of the neurofibromatosis type 1 phenotype: molecular analysis of a malignant insulinoma in a NF-1 patient. Am J Surg Pathol. 2006;30:1047\u201351.","journal-title":"Am J Surg Pathol"},{"key":"325_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1210\/jc.2008-1410","volume":"94","author":"PE Cryer","year":"2009","unstructured":"Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ, Endocrine Society. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009;94:709\u201328.","journal-title":"J Clin Endocrinol Metab"},{"key":"325_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1530\/eje.1.01901","volume":"152","author":"D Vezzosi","year":"2005","unstructured":"Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with octreosacan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol. 2005;152:757\u201367.","journal-title":"Eur J Endocrinol"},{"key":"325_CR11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.surg.2016.11.014","volume":"161","author":"C Bassi","year":"2017","unstructured":"Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584\u201391.","journal-title":"Surgery"},{"key":"325_CR12","first-page":"237","volume":"3","author":"AO Whipple","year":"1938","unstructured":"Whipple AO. The surgical therapy of hyperinsulinism. J Int Chir. 1938;3:237\u201376.","journal-title":"J Int Chir"},{"key":"325_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0889-8529(05)70084-0","volume":"28","author":"PE Cryer","year":"1999","unstructured":"Cryer PE. Symptoms of hypoglycemia, thresholds for their occurrence, and hypoglycemia unawareness. Endocrinol Metab Clin N Am. 1999;28:495\u2013500.","journal-title":"Endocrinol Metab Clin N Am"},{"key":"325_CR14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1210\/jc.2008-1416","volume":"94","author":"MH Murad","year":"2009","unstructured":"Murad MH, Coto-Yglesias F, Wang AT, Sheidaee N, Mullan RJ, Elamin MB, et al. Clinical review: drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab. 2009;94:741\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"325_CR15","doi-asserted-by":"crossref","unstructured":"Nieman LK, Chanco Turner M. Addison\u2019s disease. Clin Dermatol. 2006;276\u201380.","DOI":"10.1016\/j.clindermatol.2006.04.006"},{"key":"325_CR16","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJM199309163291203","volume":"329","author":"M A","year":"1993","unstructured":"A M, Fanelli C, Veneman T, Perriello G, Calderone S, Platanisiotis D, et al. Reversibility of unawareness of hypoglycemia in patients with insulinomas. N Engl J Med. 1993;329:834\u20139.","journal-title":"N Engl J Med"},{"key":"325_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/cen.12334","volume":"81","author":"D Gullo","year":"2014","unstructured":"Gullo D, Evans JL, Sortino G, Goldfine ID, Vigneri R. Insulin autoimmune syndrome (Hirata disease) in European Caucasians taking \u03b1-lipoic acid. Clin Endocrinol. 2014;81:204\u20139.","journal-title":"Clin Endocrinol"},{"key":"325_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.surg.2006.04.015","volume":"141","author":"A Raffel","year":"2007","unstructured":"Raffel A, Raffel A, Krausch MM, Anlauf M, Wieben D, Braunstein S, Kl\u00f6ppel G, et al. Diffuse nesidioblastosis as a cause of hyperinsulinemic hypoglycemia in adults: a diagnostic and therapeutic challenge. Surgery. 2007;141:179\u201384.","journal-title":"Surgery"},{"key":"325_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3748\/wjg.v19.i6.829","volume":"19","author":"T Okabayashi","year":"2013","unstructured":"Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, et al. Diagnosis and management of insulinoma. World J Gastroenterol. 2013;19:829\u201337.","journal-title":"World J Gastroenterol"},{"key":"325_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/qjmed\/91.4.295","volume":"91","author":"W Shi","year":"1998","unstructured":"Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG, Mcilrath EM. Localization of neuroendocrine tumours with [111In] DTPAoctreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. Q J Med. 1998;91:295\u2013301.","journal-title":"Q J Med"},{"key":"325_CR21","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/BF00181765","volume":"20","author":"EP Krenning","year":"1993","unstructured":"Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716\u201331.","journal-title":"Eur J Nucl Med"},{"key":"325_CR22","first-page":"132","volume":"28","author":"WW Herder de","year":"2005","unstructured":"de Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, et al. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Investig. 2005;28:132\u20136.","journal-title":"J Endocrinol Investig"},{"key":"325_CR23","first-page":"459","volume":"41","author":"O Schillaci","year":"2000","unstructured":"Schillaci O, Massa R, Scopinaro F. 111In-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging. J Nucl Med. 2000;41:459\u201362.","journal-title":"J Nucl Med"},{"key":"325_CR24","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1210\/jc.2009-1082","volume":"94","author":"E Christ","year":"2009","unstructured":"Christ E, Wild D, Forrer F, Br\u00e4ndle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94:4398\u2013444.","journal-title":"J Clin Endocrinol Metab"},{"key":"325_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000471879","volume":"105","author":"A Sundin","year":"2017","unstructured":"Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017;105:212\u201344.","journal-title":"Neuroendocrinology"},{"key":"325_CR26","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1136\/pgmj.73.864.640","volume":"73","author":"GV Gill","year":"1997","unstructured":"Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J. 1997;73:640\u20131.","journal-title":"Postgrad Med J"},{"key":"325_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.14310\/horm.2002.1706","volume":"15","author":"A Matej","year":"2016","unstructured":"Matej A, Bujwid H, Wro\u0144ski J. Glycemic control in patients with insulinoma. Hormones (Athens). 2016;15:489\u201399.","journal-title":"Hormones (Athens)"},{"key":"325_CR28","first-page":"120","volume":"65","author":"S Romeo","year":"2006","unstructured":"Romeo S, Milione M, Gatti A, Fallarino M, Corleto V, Morano S, Baroni MG. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. Horm Res. 2006;65:120\u20135.","journal-title":"Horm Res"},{"key":"325_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1507\/endocrj.K05-157","volume":"54","author":"M Usukura","year":"2007","unstructured":"Usukura M, Yoneda T, Oda N, Yamamoto Y, Takata H, Hasatani K, Takeda Y. Medical treatment of benign insulinoma using octreotide LAR: a case report. Endocr J. 2007;54:95\u2013101.","journal-title":"Endocr J"},{"key":"325_CR30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1055\/s-0031-1287792","volume":"120","author":"A Jawiarczyk","year":"2012","unstructured":"Jawiarczyk A, Bolanowski M, Syrycka J, Bednarek-Tupikowska G, Ka\u0142u\u017cny M, Ko\u0142odziejczyk A, Domos\u0142awski P. Effective therapy of insulinoma by using long-acting somatostatin analogue. A case report and literature review. Exp Clin Endocrinol Diabetes. 2012;120:68\u201372.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"325_CR31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ando.2013.07.001","volume":"74","author":"E Baudin","year":"2013","unstructured":"Baudin E, Caron P, Lombard-Bohas C, Tabarin A, Mitry E, Reznick Y, et al. Malignant insulinoma: recommendations for characterisation and treatment. Ann Endocrinol (Paris). 2013;74:523\u201333.","journal-title":"Ann Endocrinol (Paris)"},{"key":"325_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1530\/acta.0.1210034","volume":"121","author":"CDA Stehouwer","year":"1989","unstructured":"Stehouwer CDA, Lems WF, Fischer HRA, Hackeng WHL, Naafs MAB. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol. 1989;121:34\u201340.","journal-title":"Acta Endocrinol"},{"key":"325_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1756-9966-29-19","volume":"29","author":"M Appetecchia","year":"2010","unstructured":"Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 2010;29:19.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-018-0325-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12902-018-0325-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-018-0325-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T19:09:52Z","timestamp":1577387392000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-018-0325-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["325"],"URL":"https:\/\/doi.org\/10.1186\/s12902-018-0325-4","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"8 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval N\/A and informed consent to participate to the study was obtained from the patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"It was obtained from the patient in written form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"98"}}